scholarly journals Adeno-Associated Virus D-Sequence-Mediated Suppression of Expression of a Human Major Histocompatibility Class II Gene: Implications in the Development of Adeno-Associated Virus Vectors for Modulating Humoral Immune Response

2020 ◽  
Vol 31 (9-10) ◽  
pp. 565-574 ◽  
Author(s):  
Hyung-Joo Kwon ◽  
Keyun Qing ◽  
Selvarangan Ponnazhagan ◽  
Xu-Shan Wang ◽  
David M. Markusic ◽  
...  
Keyword(s):  
Immune Response ◽  
Humoral Immune Response ◽  
Class Ii ◽  
Major Histocompatibility ◽  
Adeno Associated Virus ◽  
Virus Vectors ◽  
Major Histocompatibility Class ◽  
Humoral Immune ◽  
Major Histocompatibility Class Ii

Evidence for multiple major histocompatibility class II X-box binding proteins

1989 ◽  
Vol 9 (11) ◽  
pp. 5219-5222
Author(s):  
A Celada ◽  
R Maki
Keyword(s):  
Dna Sequence ◽  
Binding Proteins ◽  
Regulatory Elements ◽  
Class Ii ◽  
Nuclear Factor ◽  
Major Histocompatibility ◽  
Cis Acting ◽  
Major Histocompatibility Class ◽  
Major Histocompatibility Class Ii

The X box is a loosely conserved DNA sequence that is located upstream of all major histocompatibility class II genes and is one of the cis-acting regulatory elements. Despite the similarity between all X-box sequences, each promoter-proximal X box in the mouse appears to bind a separate nuclear factor.

Characterization of cDNA clones encoding major histocompatibility class II receptors from walleye (Sander vitreus)

2018 ◽  
Vol 103 ◽  
pp. 106-114
Author(s):  
Quinn H. Abram ◽  
Kazuhiro Fujiki ◽  
Marije Booman ◽  
Emily Chin-Dixon ◽  
Guang Wei ◽  
...  
Keyword(s):  
Class Ii ◽  
Cdna Clones ◽  
Sander Vitreus ◽  
Major Histocompatibility ◽  
Major Histocompatibility Class ◽  
Major Histocompatibility Class Ii

scholarly journals Evading the AAV Immune Response in Mucopolysaccharidoses

2020 ◽  
Vol 21 (10) ◽  
pp. 3433
Author(s):  
Matthew Piechnik ◽  
Kazuki Sawamoto ◽  
Hidenori Ohnishi ◽  
Norio Kawamoto ◽  
Yasuhiko Ago ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Immune Response ◽  
Humoral Immune Response ◽  
Transgene Expression ◽  
Evidence Based ◽  
Adeno Associated Virus ◽  
Gene Therapies ◽  
Humoral Immune ◽  
Significant Challenge ◽  
Racial Background

The humoral immune response elicited by adeno-associated virus (AAV)-mediated gene therapy for the treatment of mucopolysaccharidoses (MPS) poses a significant challenge to achieving therapeutic levels of transgene expression. Antibodies targeting the AAV capsid as well as the transgene product diminish the production of glycosaminoglycan (GAG)-degrading enzymes essential for the treatment of MPS. Patients who have antibodies against AAV capsid increase in number with age, serotype, and racial background and are excluded from the clinical trials at present. In addition, patients who have undergone AAV gene therapy are often excluded from the additional AAV gene therapy with the same serotype, since their acquired immune response (antibody) against AAV will limit further efficacy of treatment. Several methods are being developed to overcome this immune response, such as novel serotype design, antibody reduction by plasmapheresis and immunosuppression, and antibody evasion using empty capsids and enveloped AAV vectors. In this review, we examine the mechanisms of the anti-AAV humoral immune response and evaluate the strengths and weaknesses of current evasion strategies in order to provide an evidence-based recommendation on evading the immune response for future AAV-mediated gene therapies for MPS.

scholarly journals Major Histocompatibility Class II Molecules in the CNS: Increased Microglial Expression at the Onset of Narcolepsy in a Canine Model

1996 ◽  
Vol 16 (15) ◽  
pp. 4588-4595 ◽  
Author(s):  
Mehdi Tafti ◽  
Seiji Nishino ◽  
Michael S. Aldrich ◽  
Wennie Liao ◽  
William C. Dement ◽  
...  
Keyword(s):  
Class Ii ◽  
Canine Model ◽  
Major Histocompatibility ◽  
Major Histocompatibility Class ◽  
Major Histocompatibility Class Ii
Sign in / Sign up

Export Citation Format

Share Document